PC-SPES studies
This article was originally published in The Tan Sheet
Executive Summary
NCCAM-funded PC-SPEStrials, on hold since BotanicLab recalled the supplement in February, will remain in limbo until at least July, NIH center says. NCCAM decision-makers currently are meeting with PC-SPES study "stakeholders," patients, researchers to determine course of action. Trial's investigators hope additional sources of PC-SPES will become available. Of the four trials, three were in vitro studies; research involving humans had not yet begun (1"The Tan Sheet" June 3, 2002, p. 5)...
You may also be interested in...
PC-SPES study decision
NCCAM anticipates releasing a decision on future of PC-SPES research "toward the end of August," NIH center states June 14. Four studies were placed on hold after February recall of the dietary supplement, coupled with sole manufacturer BotanicLab's subsequent shutdown (1"The Tan Sheet" June 3, 2002, In Brief)...
Future NCCAM Botanical Study Standards To Reflect PC-SPES Lessons
The NIH National Center for Complementary & Alternative Medicine is expected to impose stricter standards on products used in research it funds in light of the PC-SPES contamination problems
Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions
Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: